Business context and reporting period
Filing-identity discrepancy: The request identifies Achieve Life Sciences, Inc., but the supplied Form 10-Q is for OncoGenex Pharmaceuticals, Inc. This summary covers the filing provided, for the quarter ended March 31, 2016; verify the issuer before relying on it.
OncoGenex was a clinical-stage biopharmaceutical company developing cancer therapies. It had no product sales; reported revenue was collaboration revenue tied to Teva’s advance reimbursement for custirsen development costs.
Financial performance and position
Amounts below are in U.S. dollars; income and cash-flow figures are for the three months ended March 31.
| Metric | Q1 2016 | Q1 2015 or prior balance-sheet date |
|---|---|---|
| Collaboration revenue | $2.94 million | $1.37 million |
| Research and development expense | $4.64 million | $3.67 million |
| General and administrative expense | $2.30 million | $2.70 million |
| Restructuring expense | $0.43 million | None reported |
| Net loss | $3.71 million | $4.52 million |
| Net loss per share | $0.12 | $0.20 |
| Cash used in operating activities | $9.09 million | $6.44 million |
| Cash, cash equivalents and short-term investments | $46.11 million | $55.19 million at Dec. 31, 2015 |
| Total assets | $48.84 million | $58.21 million at Dec. 31, 2015 |
| Total liabilities | $14.63 million | $20.77 million at Dec. 31, 2015 |
The company reported no product revenue and continued to incur losses; a product margin is therefore not applicable. Net loss improved year over year, while operating cash use increased. The filing attributes the cash-use increase primarily to a Teva reimbursement received in Q1 2015 for prior-period development costs. Cash and investments declined by about $9.1 million from year-end. Current liabilities were $14.53 million; current assets were $47.99 million. Long-term obligations were $0.09 million, in addition to current obligations and lease liabilities.
Material changes versus the prior comparable period
- Revenue more than doubled, primarily because more deferred Teva reimbursement was recognized as custirsen development costs were incurred, particularly ENSPIRIT costs.
- R&D expense rose about 26%, mainly from higher ENSPIRIT trial costs; lower AFFINITY and investigator-sponsored apatorsen activity partly offset the increase.
- G&A expense declined about 15%, mainly due to lower administrative and professional costs.
- Net loss narrowed by about $0.8 million, including a larger noncash gain on liability-classified warrants ($0.67 million versus $0.47 million).
- Accrued clinical liabilities and deferred collaboration revenue decreased from year-end as costs were incurred and revenue recognized.
Outlook, management commentary, risks and contingencies
- Management estimated available cash, cash equivalents and short-term investments would fund currently planned operations into Q3 2017. The estimate depends on trial timing and costs and could prove inaccurate; additional funding may be needed earlier.
- Key expected milestones included AFFINITY Phase 3 results in Q3 2016; ENSPIRIT Phase 3 results in the first half of 2017; and Borealis-2 and Spruce overall-survival results in the second half of 2016.
- AFFINITY’s December 2015 analysis did not meet the prespecified survival criteria in the poor-prognosis subgroup; the trial continued after an interim analysis, with final intent-to-treat results expected in Q3 2016. ENSPIRIT results remained event-driven and timing-dependent.
- Prior studies presented mixed or unfavorable findings: custirsen’s SYNERGY trial did not meet its primary overall-survival endpoint; apatorsen’s Rainier trial did not show an overall-survival benefit; and Spruce did not reach statistical significance for its primary progression-free-survival endpoint. Management cautioned that exploratory subgroup findings were not proof of efficacy.
- In February 2016, the company reduced its workforce by 11 employees, about 27% of its prior workforce, and recorded approximately $0.4 million in largely severance costs. Management expected the cuts and other spending reductions to extend the cash runway.
- Teva’s collaboration had ended; the company regained custirsen rights and assumed post-2014 development costs. The remaining Teva holdback was almost fully deducted, and only nominal further receipts were expected.
- Ionis litigation: Ionis sought at least $10 million and a declaration that it could terminate a license, alleging an unpaid share of Teva termination consideration. OncoGenex disputed that any amount was due and said it would defend the case. The company could not estimate a reasonably possible loss; an adverse outcome could affect its financial position, development plans and licensed rights.
- A separate $1.3 million lease-termination payment was recorded as a liability because management assessed that the required clinical and financing conditions were more likely than not to occur.
- Other significant risks included clinical-trial failure or delay, reliance on third-party manufacturers and trial operators, financing needs, and Nasdaq’s $1 minimum bid-price requirement. The company had until August 23, 2016 to regain compliance. Management reported disclosure controls were effective at quarter-end and no material internal-control changes during the quarter.
Most important facts for investors to verify
- Whether this OncoGenex filing is the intended filing for the requested company, Achieve Life Sciences.
- Actual cash burn, trial costs and liquidity runway against management’s Q3 2017 estimate, including funding needs after trial readouts.
- Final AFFINITY and ENSPIRIT outcomes and whether trial timing or results materially changed development plans.
- Status and potential financial or licensing impact of the Ionis lawsuit, including any court rulings or settlement.
- Nasdaq bid-price compliance, financing availability and the realized savings and operational effects of the workforce reduction.